Septodont North America has announced the US launch of Flavalta™ (lidocaine hydrochloride 2% with epinephrine 1:100,000), a local anesthetic formulation that incorporates flavoring agents. According to the company, it is the first lidocaine formulation to include flavoring agents and represents its first major reformulation of a dental local anesthetic in more than 25 years.
Lidocaine has been widely used in dentistry since its introduction in 1948 and remains a commonly used local anesthetic. Flavalta incorporates sodium saccharin, a nonnutritive sweetener, and L-serine, a naturally occurring amino acid with flavor-enhancing properties. Both ingredients have been approved by the US Food and Drug Administration for use as sweetening and flavor-enhancing agents in food, beverages, and pharmaceutical products.
The company said patient feedback and market research identified taste as an aspect of the anesthetic experience that could be improved.
"There is nothing better than to take a concern of our dentist customers and their patients and give them a solution," said Paul Mondock, President North America & Global Sales Services." By adding flavoring agents while maintaining the reliability and clinical performance practitioners depend on, Flavalta represents the next evolution of local anesthesia."
According to Septodont, Flavalta provides an average onset of less than 2 minutes for infiltration anesthesia and 2 to 4 minutes for nerve block anesthesia. The company reports an approximate duration of 60 minutes for infiltration procedures and approximately 90 minutes of pulpal anesthesia for nerve block procedures.
Additional product features include a methylparaben-free formulation intended to reduce the risk of allergic reactions in sensitive patients, latex-free components that contain no natural rubber latex, and terminally sterilized cartridges.
Flavalta lidocaine hydrochloride 2% with epinephrine 1:100,000 is available through authorized dental distributors in the United States. Septodont recommends that the product be used in accordance with its approved prescribing information.
Figures and Images
Flavalta™
